Biomage Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biomage Limited - overview
Established
2019
Location
Edinburgh, -, UK
Primary Industry
Biotechnology
About
Based in Edinburgh, UK, and founded in 2019 by CEO Adam Kurkiewicz, Iva Babukova, Vicky Morrison, and Peter Kharchenko, Biomage Limited, a. k. a. Biomage operates as a biotechnology research company that engages in biomedical data analysis for researchers to visualize individual cells's gene activity.
In January 2024, Parse Biosciences, Inc. , a portfolio company of Marshall Wace, Janus Henderson Investors, Logos Capital, Marshall Wace, Bioeconomy Capital, Soleus Capital Management, and Saras Capital, acquired Biomage, Limited from Luminous Ventures, SOSV, and IndieBio. Biomage offers Cellenics®, an open-source software tool for analyzing single-cell RNA sequencing data. Cellenics® enables users to process, explore, and visualize their data from count matrices to publication-ready figures.
The platform supports both local and systemic deployment and integrates with existing data storage and pipelining tools.
Current Investors
SOSV, IndieBio, Luminous Ventures
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Healthcare IT, Medical Software, Analytics & Performance Software
Website
www.biomage.net
Verticals
Cloud Computing, HealthTech
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.